An Integrated Targeting Drug Delivery System Based On The Combine Of Gaphdiyne And MOFs For Cancer Therapy With Visual Effects

Malignant tumor is the first killer of life and health,and the treatment of tumors cannot be ignored.Drug therapy is one of the most commonly cancer treatment.However,conventional drug delivery systems can hardly satisfy this application due to their various drawbacks in either low loading content,uncontrolled release,nontargeting or the biotoxicity.In order to solve these shortcomings of traditional drug delivery systems,the integration of diagnosis,treatment,or multimodal theranostics in one pot for personalized medicine has been regarded as a promising strategy for cancer treatment.1)Here,we have developed a multifunctional two-dimensional targeting drug delivery system,Fe₃O₄@UiO-66-NH₂/graphdiyne（FUGY）,based on the binding of a novel two-dimensional material graphdiyne（GDY）with a metal organic frameworks（MOFs）structure--Fe₃O₄@UiO-66-NH₂（FU）.The FUGY structure with superior ability of magnetic targeting was constructed by an in situ growth method,which was surface-installed with GDY via amide bond as a carrier of anticancer drugs.The anticancer drug doxorubicin（DOX）was loaded onto FUGY and served as both an anticancer drug to treat the tumor and a fluorescence probe to ascertain the location of FUGY.The morphology and physicochemical properties of FUGY were characterized by SEM,TEM,particle size analyzer,XRD,Raman,infrared spectroscopy,hysteresis loop,BET,respectively.The results show that the synthesized FUGY has regular shape,large specific surface area,good stability,good dispersibility in aqueous solution,and is potential to be drug carriers.2)DOX loading and release abilities of FUGY were determined by UV absorption curve,the results showed that FUGY exhibited a high drug loading content of 43.8%and effective drug release at p H 5.0.In particular,fluorescent imaging demonstrated that FUGY could accumulate more anticancer drugs in tumor positions than conventional drug.Furthermore,FUGY exhibited superior therapeutic efficiencies with negligible side effects compared to the direct administration of free DOX bothin vitro and in vivo,the inhibited rate of tumor was as high as 77.5%.The obtained FUGY drug delivery system possesses ideal biocompatibility,sustained drug release,effective chemotherapeutic efficacy,specific targeting abilities,as well as excellent fluorescence imaging capacity.Such a system integrating diagnosis,treatment,and multimodal theranostics in a single platform by a simple and efficient strategy,aiming for facilitating new possibilities for multifunctional drug delivery system.